Focal pulsed field ablation in complex atrial tachycardia: First clinical experience and 1- year outcome.
Catheter ablation
ablation of atrial tachycardia
focal pulsed-field ablation
linear lesions
pulsed-field ablation
Journal
Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
received:
01
04
2024
revised:
13
06
2024
accepted:
02
07
2024
medline:
18
7
2024
pubmed:
18
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Pulsed-field ablation (PFA) has become increasingly important in the treatment of cardiac arrhythmias. In addition to single-shot devices mainly used for pulmonary vein isolation, focal PFA may provide a treatment option increasing the versatility of the technique. The study objective was to provide data on feasibility, safety and long-term outcome of focal PFA for the ablation of complex atrial tachycardia (AT). All consecutive patients (n=34) with complex AT treated at our department between 2022 and 2023 with a focal PFA system (CENTAURI™, Galvanize therapeutics, San Carlos, USA) were included. The majority of patients (32/34 pts) had undergone at least one prior radiofrequency ablation. Established contact-force sensing catheters were used for PFA application in combination with a PFA generator. Pulse electric field (PEF) trains were conducted in a R-wave triggered manner. Acute procedural success was accomplished in all patients. PFA included creation of 51 linear lesions and (re)isolation of 12 pulmonary veins. Mean procedure duration was 102.7 ± 30.3 min, with a LA dwell time of 75.0 ± 24.7 min. Mean fluoroscopy duration was 8.7 ± 5.3 min. No complications occurred. After a mean follow-up of 340.9 ± 130.1 days, recurrence of any AT occurred in 15 patients (44.1%). During 9 reablations, 3 gaps in previously created linear lesions were detected whereas the majority of recurrences (n=6) was not related to previous PFA lesion creation. Focal pulsed-field ablation of complex AT substrates was safe and efficient. Acute procedural success was 100%; after one year, the majority of patients were in sinus rhythm. A minority of recurrences was caused by insufficient PFA lesion creation.
Sections du résumé
BACKGROUND
BACKGROUND
Pulsed-field ablation (PFA) has become increasingly important in the treatment of cardiac arrhythmias. In addition to single-shot devices mainly used for pulmonary vein isolation, focal PFA may provide a treatment option increasing the versatility of the technique.
OBJECTIVE
OBJECTIVE
The study objective was to provide data on feasibility, safety and long-term outcome of focal PFA for the ablation of complex atrial tachycardia (AT).
METHODS
METHODS
All consecutive patients (n=34) with complex AT treated at our department between 2022 and 2023 with a focal PFA system (CENTAURI™, Galvanize therapeutics, San Carlos, USA) were included. The majority of patients (32/34 pts) had undergone at least one prior radiofrequency ablation. Established contact-force sensing catheters were used for PFA application in combination with a PFA generator. Pulse electric field (PEF) trains were conducted in a R-wave triggered manner.
RESULTS
RESULTS
Acute procedural success was accomplished in all patients. PFA included creation of 51 linear lesions and (re)isolation of 12 pulmonary veins. Mean procedure duration was 102.7 ± 30.3 min, with a LA dwell time of 75.0 ± 24.7 min. Mean fluoroscopy duration was 8.7 ± 5.3 min. No complications occurred. After a mean follow-up of 340.9 ± 130.1 days, recurrence of any AT occurred in 15 patients (44.1%). During 9 reablations, 3 gaps in previously created linear lesions were detected whereas the majority of recurrences (n=6) was not related to previous PFA lesion creation.
CONCLUSION
CONCLUSIONS
Focal pulsed-field ablation of complex AT substrates was safe and efficient. Acute procedural success was 100%; after one year, the majority of patients were in sinus rhythm. A minority of recurrences was caused by insufficient PFA lesion creation.
Identifiants
pubmed: 39019385
pii: S1547-5271(24)02905-9
doi: 10.1016/j.hrthm.2024.07.024
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.